{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:49:54Z","timestamp":1788569394225,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-026-08317-2","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:05:29Z","timestamp":1770210329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface area"],"prefix":"10.1007","volume":"313","author":[{"given":"A.","family":"Englisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Eissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dannehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Englisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Hartkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Y.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Grischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. L.","family":"Volmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"8317_CR1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","volume":"30","author":"JJ Griggs","year":"2012","unstructured":"Griggs JJ, Mangu PB, Anderson H et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 30:1553\u20131561. https:\/\/doi.org\/10.1200\/JCO.2011.39.9436","journal-title":"J Clin Oncol"},{"key":"8317_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81792-6","volume":"11","author":"W Bouleftour","year":"2021","unstructured":"Bouleftour W, Viard A, Mery B et al (2021) Body surface area capping may not improve cytotoxic drugs tolerance. Sci Rep 11:2431. https:\/\/doi.org\/10.1038\/s41598-021-81792-6","journal-title":"Sci Rep"},{"key":"8317_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281\u20131288. https:\/\/doi.org\/10.1200\/JCO.1984.2.11.1281","journal-title":"J Clin Oncol"},{"key":"8317_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-131","volume":"11","author":"S Loibl","year":"2011","unstructured":"Loibl S, Skacel T, Nekljudova V et al (2011) Evaluating the impact of relative total dose intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131. https:\/\/doi.org\/10.1186\/1471-2407-11-131","journal-title":"BMC Cancer"},{"key":"8317_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70187-8","volume":"10","author":"W Qi","year":"2020","unstructured":"Qi W, Wang X, Gan L et al (2020) The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. Sci Rep 10:13241. https:\/\/doi.org\/10.1038\/s41598-020-70187-8","journal-title":"Sci Rep"},{"key":"8317_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","volume":"10","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Sparreboom A (2013) Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 10:451\u2013459. https:\/\/doi.org\/10.1038\/nrclinonc.2013.108","journal-title":"Nat Rev Clin Oncol"},{"key":"8317_CR7","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.21.00471","volume":"39","author":"JJ Griggs","year":"2021","unstructured":"Griggs JJ, Bohlke K, Balaban EP et al (2021) Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol 39:2037\u20132048. https:\/\/doi.org\/10.1200\/JCO.21.00471","journal-title":"J Clin Oncol"},{"key":"8317_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0881-z","volume":"31","author":"JP Carroll","year":"2014","unstructured":"Carroll JP, Protani MM, Nguyen L et al (2014) Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Med Oncol 31:881. https:\/\/doi.org\/10.1007\/s12032-014-0881-z","journal-title":"Med Oncol"},{"key":"8317_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jgo.2017.11.007","volume":"9","author":"VA Morrison","year":"2018","unstructured":"Morrison VA, McCall L, Muss HB et al (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: results from cancer and leukemia group B (CALGB) trial 49907 (alliance A151436). J Geriatr Oncol 9:228\u2013234. https:\/\/doi.org\/10.1016\/j.jgo.2017.11.007","journal-title":"J Geriatr Oncol"},{"key":"8317_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.clon.2016.02.003","volume":"28","author":"H Lote","year":"2016","unstructured":"Lote H, Sharp A, Redana S et al (2016) Febrile neutropenia rates according to body mass index and dose capping in women receiving chemotherapy for early breast cancer. Clin Oncol 28:597\u2013603. https:\/\/doi.org\/10.1016\/j.clon.2016.02.003","journal-title":"Clin Oncol"},{"key":"8317_CR11","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/annonc\/mdw315","volume":"27","author":"J Furlanetto","year":"2016","unstructured":"Furlanetto J, Eiermann W, Marm\u00e9 F et al (2016) Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. Ann Oncol 27:2053\u20132059. https:\/\/doi.org\/10.1093\/annonc\/mdw315","journal-title":"Ann Oncol"},{"key":"8317_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.breast.2017.04.001","volume":"33","author":"A Farr","year":"2017","unstructured":"Farr A, Stolz M, Baumann L et al (2017) The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. Breast 33:153\u2013158. https:\/\/doi.org\/10.1016\/j.breast.2017.04.001","journal-title":"Breast"},{"key":"8317_CR13","unstructured":"US. Department of Health And Human Services (2017) Hrsg. Common terminology criteria for adverse events (CTCAE)"},{"key":"8317_CR14","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/ajhp\/58.18.1760","volume":"58","author":"RJ Plumridge","year":"2001","unstructured":"Plumridge RJ, Sewell GJ (2001) Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health-Syst Pharm 58:1760\u20131764. https:\/\/doi.org\/10.1093\/ajhp\/58.18.1760","journal-title":"Am J Health-Syst Pharm"},{"key":"8317_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","volume":"139","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Tomita D et al (2013) A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat 139:863\u2013872. https:\/\/doi.org\/10.1007\/s10549-013-2582-2","journal-title":"Breast Cancer Res Treat"},{"key":"8317_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4143\/crt.2020.928","volume":"53","author":"KH Lee","year":"2021","unstructured":"Lee KH, Chie EK, Im SA et al (2021) Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine in patients with resected pancreatic cancer. Cancer Res Treat 53:1096\u20131103. https:\/\/doi.org\/10.4143\/crt.2020.928","journal-title":"Cancer Res Treat"},{"key":"8317_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","volume":"100","author":"M Shayne","year":"2006","unstructured":"Shayne M, Crawford J, Dale DC et al (2006) Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 100:255\u2013262. https:\/\/doi.org\/10.1007\/s10549-006-9254-4","journal-title":"Breast Cancer Res Treat"},{"key":"8317_CR18","doi-asserted-by":"publisher","first-page":"28415","DOI":"10.1038\/s41598-025-14279-3","volume":"15","author":"B Wafa","year":"2025","unstructured":"Wafa B, Aurane R, Fabien T et al (2025) Influence of capping chemotherapy prescriptions on efficacy and tolerability in medium and high-risk early-stage breast cancer. Sci Rep 15:28415. https:\/\/doi.org\/10.1038\/s41598-025-14279-3","journal-title":"Sci Rep"},{"key":"8317_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3572","volume":"15","author":"B Pajares","year":"2013","unstructured":"Pajares B, Poll\u00e1n M, Mart\u00edn M et al (2013) Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 15:R105. https:\/\/doi.org\/10.1186\/bcr3572","journal-title":"Breast Cancer Res"},{"key":"8317_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.clon.2020.05.004","volume":"32","author":"CGV Slawinski","year":"2020","unstructured":"Slawinski CGV, Barriuso J, Guo H et al (2020) Obesity and cancer treatment outcomes: interpreting the complex evidence. Clin Oncol 32:591\u2013608. https:\/\/doi.org\/10.1016\/j.clon.2020.05.004","journal-title":"Clin Oncol"},{"key":"8317_CR21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.3390\/cancers15092526","volume":"15","author":"A LeVee","year":"2023","unstructured":"LeVee A, Mortimer J (2023) The challenges of treating patients with breast cancer and obesity. Cancers 15:2526. https:\/\/doi.org\/10.3390\/cancers15092526","journal-title":"Cancers"},{"key":"8317_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1017\/S0029665118000447","volume":"77","author":"A Heetun","year":"2018","unstructured":"Heetun A, Cutress RI, Copson ER (2018) Early breast cancer: why does obesity affect prognosis? Proc Nutr Soc 77:369\u2013381. https:\/\/doi.org\/10.1017\/S0029665118000447","journal-title":"Proc Nutr Soc"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08317-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:05:31Z","timestamp":1770210331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08317-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8317"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08317-2","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AE: Honoraria from Novartis and AstraZeneca; DD: Honoraria from AstraZeneca, Gilead, Novartis, Daiichi Sankyo, Onkowissen, Oncologics, and Pfizer; travel support from Gilead and Daiichi Sankyo; JE: Honoraria from AstraZeneca; ADH: Speakers bureau for Roche, Novartis, Lilly, MSD, AstraZeneca, Daiichi Sankyo, Seagen, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, and Eisai. Honoraria from Roche, Novartis, Lilly, MSD, AstraZeneca, Seagen, GSK, ExactScience, Riemser, Teva, Onkowissen, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Eisai, and Daiichi Sankyo. Consulting\/advisory role for Roche, Novartis, MSD, AstraZeneca, GSK, ExactScience, Riemser, Teva, Onkowissen, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, and Daiichi Sankyo. Travel support from Roche, Novartis, Lilly, AstraZeneca, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, and Daiichi Sankyo. Research grants from ExactScience and Veracyte. Authorship honoraria from AstraZeneca and Menarini Stemline; SYB: Honoraria from Roche, Novartis, Pfizer, MSD, Teva, and AstraZeneca; LLV: Honoraria from Novartis; TE: Honoraria from Abbvie, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, GSK, MSD, Novartis, Pfizer, Pierre Fabre, and Roche. Consulting\/advisory role for AstraZeneca, Eli Lilly, Gilead, GSK, MSD, Novartis, Pfizer, Pierre Fabre, Roche, and Stemline. Travel support from Abbvie, Eli Lilly, Gilead, Novartis, Pfizer, and Stemline. All remaining authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the principles of the Declaration of Helsinki and received approval from the Ethics Committee of the University Hospital of T\u00fcbingen (800\/2022BO2).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"75"}}